Evidence map›Paper›PMID 37086619›Full record

ArticleTranslational oncology2023

G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells.

Andrea K Corbet, Emmanuel Bikorimana, Raya I Boyd, Doha Shokry, Kelly Kries, Ayush Gupta, Anneliese Paton, Zhengyang Sun, Zeeshan Fazal, Sarah J Freemantle and 3 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Recent advances on the role of G0S2.Discover oncology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Andrea K CorbetDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Emmanuel BikorimanaDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Raya I BoydDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Doha ShokryDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Kelly KriesDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Ayush GuptaDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Anneliese PatonDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Zhengyang SunDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Zeeshan FazalDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Sarah J FreemantleDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Erik R NelsonDepartment of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA; Carle Illinois College of Medicine University of Illinois Urbana-Champaign, Urbana IL 61801, USA; Carl R. Woese Institute for Genomic Biology, Anticancer Discovery from Pets to People Theme, University of Illinois Urbana-Champaign, Urbana IL 61801, USA; Cancer Center of Illinois, University of Illinois Urbana-Champaign, Urbana IL 61801, USA.
Michael J SpinellaDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA; Carle Illinois College of Medicine University of Illinois Urbana-Champaign, Urbana IL 61801, USA; Carl R. Woese Institute for Genomic Biology, Anticancer Discovery from Pets to People Theme, University of Illinois Urbana-Champaign, Urbana IL 61801, USA; Cancer Center of Illinois, University of Illinois Urbana-Champaign, Urbana IL 61801, USA. Electronic address: spinella@illinois.edu.
Ratnakar SinghDepartment of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA. Electronic address: rsingh02@illinois.edu.
University of Illinois Urbana-Champaign · US

Funding

Research Training Program in Toxicology and Environmental HealthT32ES007326 · NIEHS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI Jodi A. Flaws · 2000 to 2026
$8.7M
DNA Methylation Inhibitor Therapy for Testicular CancerR01CA211875 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI SPINELLA, MICHAEL J · 2018 to 2022
$2.5M
NCI NIH HHS R01 CA211875NIEHS NIH HHS T32 ES007326
6 · The paper itself

Abstract

G0/G1 switch gene 2 (G0S2) is known to inhibit lipolysis by inhibiting adipose triglyceride lipase (ATGL). In this report, we dissect the role of G0S2 in ER+ versus ER- breast cancer. Overexpression of G0S2 in ER- cells increased cell proliferation, while G0S2 overexpression in ER+ cells decreased cell proliferation. Transcriptome analysis revealed that G0S2 mediated distinct but overlapping transcriptional responses in ER- and ER+ cells. G0S2 reduced genes associated with an epithelial phenotype, especially in ER- cells, including CDH1, ELF3, STEAP4 and TACSTD2, suggesting promotion of the epithelial-mesenchymal transition (EMT). G0S2 also repressed estrogen signaling and estrogen receptor target gene signatures, especially in ER+ cells, including TFF1 and TFF3. In addition, G0S2 overexpression increased cell migration in ER- cells and increased estrogen deprivation sensitivity in ER+ cells. Interestingly, two genes downstream of ATGL in fat utilization and very important in steroid hormone biosynthesis, HMGCS1 and HMGCS2, were downregulated in G0S2 overexpressing ER+ cells. In addition, HSD17B11, a gene that converts estradiol to its less estrogenic derivative, estrone, was highly upregulated in G0S2 overexpressing ER+ cells, suggesting G0S2 overexpression has a negative effect on estradiol production and maintenance. High expression of G0S2 and HSD17B11 was associated with improved relapse-free survival in breast cancer patients while high expression of HMGSC1 was associated with poor survival. Finally, we deleted G0S2 in breast cancer-prone MMTV-PyMT mice. Our data indicates a complex role for G0S2 in breast cancer, dependent on ER status, that may be partially mediated by suppression of the estrogen signaling pathway.

Indexed as

AntiestrogenBreast cancerEpithelial mesenchymal transitionEstrogen receptorG0S2

Identifiers

PMID37086619
PMCPMC10214302
OpenAlexW4366494219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.